News

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…

1 month ago

Tenon Medical Announces Closing of $2.85 Million At-The-Market PIPE Financing

LOS GATOS, CA / ACCESS Newswire / November 14, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a…

1 month ago

TRNR Reports Record Third Quarter 2025 Results with 139% YoY Growth; Reiterates 2025 Pro Forma Revenue Guidance of $80M+ To Be Driven by Completion of Sportstech Acquisition

Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1)Company Reports Record Quarterly Revenue of $4.8 Million; Net…

1 month ago

Forecasted Heavy Rain Prompts Postponement of Compassion Center Coalition for Patient Rights Inaugural Hoedown to Dec. 13

Outdoor toy-drive event rescheduled to prioritize safety as Las Vegas faces 70-90% chance of rain on Saturday LAS VEGAS, NEVADA…

1 month ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

     Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding…

1 month ago

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC…

1 month ago

Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

1 month ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024…

1 month ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –…

1 month ago

Nemysis Limited Announces Investment by Kolinpharma Through Its Parent Company IGEA Holding S.p.A.

DUBLIN, IE / ACCESS Newswire / November 14, 2025 / Nemysis Limited is pleased to announce the signing of a…

1 month ago